Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...

Ever since U.S. President Donald Trump has taken office, one of the many things that constantly dominated headlines was his ...

Vertiv's AI-driven growth lags behind top players, with risks to margins and a premium valuation despite modest sales growth ...

Vale remains attractive with 30% upside; focus on efficiency and safety offsets the challenging iron ore scenario. Read what ...

RISR delivered strong returns with negative duration and skilled active management, but hedging benefits may be fading amid ...

The S&P 500 ( SP500) stock index may look pricey at the surface, but beneath the index-level froth, some policy-linked investment themes are still trading at discounts, said Savita Subramanian, equity ...

IVV shows the S&P 500 is 10% overvalued, with energy leading in value and quality, while key sectors remain undervalued. Find ...

Armada Hoffler has struggled with a dividend cut and 20% drop, but its ultra-low P/FFO suggests deep value potential. Read ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

Dell's AI-driven growth boasts a $14.4B backlog and strong partnerships. Read more DELL stock's long-term potential, market ...

The latest PCE data confirms cooling inflation, but tariff concerns and Fed caution dampen the impact. Check out where market ...

Solid earnings growth, reaccelerating advertising, and robust e-commerce drive Kuaishou Technology's future. Read more on ...